课题基金 / 基金详情

Antenatal Betamethasone in Late Preterm Gestation Lambs

Antenatal Betamethasone in Late Preterm Gestation Lambs
晚期早产羔羊的产前倍他米松
批准号:
7572417
负责人:
Satyanarayana Lakshminrusimha
金额:
$7.93万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-05-06 至 2011-04-30
关键词:
AccountingAdenylate CyclaseAdrenergic ReceptorAffectAirAmerican College of Obstetricians and GynecologistsAnimal ModelAntibiotic A23187ApicalArginineArteriesAtrial Natriuretic FactorBathingBetamethasoneBiochemical PathwayBirthBlindedBlood CirculationBlood VesselsBlood gasBreathingCalciumCathetersCesarean sectionCholineClinical ProtocolsCyclic AMPCyclic GMPDilution TechniquesDiscipline of obstetricsDiseaseDoseDropsEnvironmental air flowEnzymesEpoprostenolEpoprostenol ReceptorsEvaluationEventFetal LungFetusForskolinFreezingGenerationsGestational AgeGlucocorticoidsGuanylate CyclaseHistologyHourHumanIncidenceIncubatedInfantInjection of therapeutic agentInterventionIntramuscularIonophoresIsoproterenolLipidsLiquid substanceLungLung ComplianceMeasurementMeasuresMediatingMediator of activation proteinMedicalMesenteric ArteriesMessenger RNAMonitorMorbidity - disease rateMothersMuscle relaxation phaseNatriuretic PeptidesNewborn InfantNitric OxideNitric Oxide DonorsNorepinephrineNorth AmericaParticulatePathway interactionsPenicillaminePeptide ReceptorPhospholipidsPhysiologicalPhysiologyPlacebosPractice GuidelinesPregnancyPremature BirthPremature InfantPremature LaborProductionProlonged PregnancyProstacyclin synthaseProstaglandinsProstaglandins IProteinsProtocols documentationPulmonary HypertensionPulmonary Surfactant-Associated Protein APulmonary Vascular ResistancePulmonary artery structurePulmonary function testsRandomizedRelaxationReportingResearch DesignRespiratory distressRiskSalineSamplingSecondary toSeveritiesSmooth MuscleSoluble Guanylate CyclaseSourceSteroidsStructure of parenchyma of lungSurface TensionTerbutalineTestingThird Pregnancy TrimesterTimeTissuesTocolysisTracheaType II Epithelial Receptor CellVasodilationVentilatorWomanWorkabsorptionalveolar type II cellatrial natriuretic factor receptor Abeta adrenergic agentbeta-adrenergic receptorblue dextranconstrictionfetalhemodynamicshigh riskhuman NOS3 proteinimprovedin uteroin vivoinsightinstrumentintraventricular hemorrhagelung lobemortalityneonatal morbiditypostnatalpregnantpressurepreventpublic health relevancereceptorresearch studyrespiratoryrespiratory distress syndromeresponsesurfactantwet lung

项目摘要

项目成果

Satyanarayana Lakshminrusimha的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The incidence of late preterm births (defined as births at 34 0/7 to 36 6/7 wk gestation) have been steadily increasing over the past decade and account for the ~ 75% of all preterm births. Respiratory morbidity from disorders of transition including pulmonary hypertension (impaired pulmonary vasodilation), transient tachypnea of newborn (inadequate lung liquid clearance) and respiratory distress syndrome (inadequate surfactant production and release) affect late preterm infants at a higher rate than infants of more advanced gestational age. Practice guidelines of the American College of Obstetricians and Gynecologists (ACOG) recommend tocolysis and glucocorticoids to women in preterm labor up to 34 wk gestation. However, beyond 34 wk efforts are no longer directed at prolonging pregnancy or enhancing fetal maturity. Moreover, because of the inherent inaccuracy of pregnancy dating with margins of error up to 3 wk in the third trimester, inductions of labor and elective cesarean section performed at "presumed term" might inadvertently contribute to the increasing incidence of late preterm birth. The Antenatal Steroids for Term Cesarean Section study reported that two doses of antenatal betamethasone significantly reduced respiratory morbidity in > 37 wk infants born by elective cesarean section. Administration of antenatal glucocorticoids to < 34 wk gestation mothers in preterm labor undoubtedly reduces a number of neonatal morbidities including respiratory distress and intraventricular hemorrhage. Given the promising results in infants > 37 wk in a single study, research evaluating the pulmonary physiological effects and benefits (or lack there of) of antenatal glucocorticoids for preterm labor between 34 and 36 6/7 wk is important. We propose to gain such insight by administering betamethasone to pregnant ewes prior to elective cesarean section. It may not be possible to prevent delivery for 48 h after initiation of an antenatal steroid course. Hence we plan to test two protocols: one dose of betamethasone administered 24 h prior to delivery and two doses administered 48 h and 24 h prior to delivery in this proposal. Late preterm lambs (134 d gestation, term ~ 145 d) delivered by elective cesarean section following two, one or no doses of antenatal betamethasone will either be sacrificed at birth (for evaluation of pulmonary vascular reactivity, lung liquid status, compliance and surfactant production and release) or instrumented for evaluation of pulmonary vascular resistance, oxygenation and ventilation for 6 h. We will study the changes in important mediators of pulmonary transition at birth such as nitric oxide, beta adrenergic agents, natriuretic peptides and prostaglandins secondary to antenatal glucocorticoid use. We hypothesize that antenatal administration of either one or two doses of betamethasone will enhance pulmonary vasodilation, lung liquid reabsorption and surfactant production in late preterm lambs delivered by cesarean section. These studies are likely to have an impact on the clinical protocol for use of antenatal steroids, changing current practice. PUBLIC HEALTH RELEVANCE: The number of births at 34 to 37 weeks of gestation, often referred to as late preterm births, delivered by cesarean section is rapidly increasing in North America. Treating late preterm pregnant mothers in labor with betamethasone (a steroid) may reduce the risk of respiratory complications and mortality in their infants. We intend to administer betamethasone to late preterm gestation ewes to study the benefit and mechanism of this treatment in fetal lambs delivered by cesarean section.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Optimal Oxygenation in Neonatal Lung Injury
  • 批准号:
    10734639
  • 项目类别:
  • 资助金额:
    $68.78万
  • 财政年份:
    2023
  • 负责人:
    Satyanarayana Lakshminrusimha
  • 依托单位:
Optimal Oxygenation in Neonatal Lung Injury
Optimal Oxygenation in Neonatal Lung Injury
  • 批准号:
    9627355
  • 项目类别:
  • 资助金额:
    $27.17万
  • 财政年份:
    2012
  • 负责人:
    Satyanarayana Lakshminrusimha
  • 依托单位:
Optimal Oxygenation in Neonatal Lung Injury
海外基金